Welcome to our dedicated page for Inspiremd SEC filings (Ticker: NSPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading InspireMD鈥檚 dense filings can feel like a clinical trial of patience. Hundreds of pages track MicroNet-covered stent efficacy, FDA milestones and global trial costs鈥攄etails that drive the share price but hide in footnotes.
Our platform turns that complexity into clarity. Whether you need the full InspireMD annual report 10-K simplified or the latest InspireMD quarterly earnings report 10-Q filing, Stock Titan鈥檚 AI pinpoints R&D spend, cash runway and pivotal trial updates in seconds. AG真人官方-time alerts surface every InspireMD insider trading Form 4 transactions notice, so you never miss executive stock moves.
Here鈥檚 what you can uncover today:
- Form 4 dashboards for InspireMD executive stock transactions Form 4 with real-time push.
- Instant summaries that answer 鈥淲hat changed in this 10-Q?鈥� for busy clinicians and fund managers.
- 8-K trackers that flag device-approval news鈥�InspireMD 8-K material events explained.
- Proxy insights that decode InspireMD proxy statement executive compensation versus peer med-tech firms.
No more line-by-line reading to find trial enrollment numbers or manufacturing cost shifts. Our expert layer explains ratios, spotlights risk wording and links related exhibits, making understanding InspireMD SEC documents with AI straightforward.
Save hours, spot inflection points earlier and answer questions like 鈥淚s management buying shares?鈥� or 鈥淗ow much was spent on CGuard鈥檚 FDA study?鈥� with confidence. Every filing, from the smallest 3-page 8-K to the exhaustive 300-page 10-K, is updated the moment it hits EDGAR鈥攕o your analysis stays ahead of the next catheter deployment.
Vital Energy, Inc. (VTLE) Form 4: Director Lori A. Lancaster reported the acquisition of 2,141 deferred stock units (DSUs) on 07/31/2025. The award, issued at a cost basis of $0 under the company鈥檚 Omnibus Equity Incentive Plan, represents partial payment of her board retainer and fees. Each DSU converts into one share of common stock upon settlement. After the grant, Lancaster directly owns 16,197 DSUs. Table I shows no open-market activity in common shares, underscoring that the filing reflects routine, compensation-related equity rather than an investment trade. No 10b5-1 plan was indicated, and the transaction does not alter the overall share count or governance structure. Investors should view this as a standard refresh of equity compensation rather than a signal of changing insider sentiment.
On 30 Jul 2025, InspireMD, Inc. (NSPR) director Dr. Gary S. Roubin reported an open-market purchase of 41,322 common shares at $2.42 per share under a private-placement exemption (Securities Act 搂4(a)(2)). Following the transaction, the director鈥檚 directly held position increased to 608,425 shares. No derivative securities were involved, and the filing contains no sales or dispositions.
The single transaction represents an insider adding to his stake rather than trimming holdings, which can be viewed as a signal of personal confidence in the company鈥檚 prospects. The form was signed on 01 Aug 2025 by attorney-in-fact Craig Shore.
On 30 Jul 2025, InspireMD, Inc. (NSPR) director Dr. Gary S. Roubin reported an open-market purchase of 41,322 common shares at $2.42 per share under a private-placement exemption (Securities Act 搂4(a)(2)). Following the transaction, the director鈥檚 directly held position increased to 608,425 shares. No derivative securities were involved, and the filing contains no sales or dispositions.
The single transaction represents an insider adding to his stake rather than trimming holdings, which can be viewed as a signal of personal confidence in the company鈥檚 prospects. The form was signed on 01 Aug 2025 by attorney-in-fact Craig Shore.
On 30 Jul 2025, InspireMD, Inc. (NSPR) director Dr. Gary S. Roubin reported an open-market purchase of 41,322 common shares at $2.42 per share under a private-placement exemption (Securities Act 搂4(a)(2)). Following the transaction, the director鈥檚 directly held position increased to 608,425 shares. No derivative securities were involved, and the filing contains no sales or dispositions.
The single transaction represents an insider adding to his stake rather than trimming holdings, which can be viewed as a signal of personal confidence in the company鈥檚 prospects. The form was signed on 01 Aug 2025 by attorney-in-fact Craig Shore.
On 30 Jul 2025, InspireMD, Inc. (NSPR) director Dr. Gary S. Roubin reported an open-market purchase of 41,322 common shares at $2.42 per share under a private-placement exemption (Securities Act 搂4(a)(2)). Following the transaction, the director鈥檚 directly held position increased to 608,425 shares. No derivative securities were involved, and the filing contains no sales or dispositions.
The single transaction represents an insider adding to his stake rather than trimming holdings, which can be viewed as a signal of personal confidence in the company鈥檚 prospects. The form was signed on 01 Aug 2025 by attorney-in-fact Craig Shore.
Itron, Inc. (NASDAQ: ITRI) filed a Form 8-K dated 31 Jul 2025 to report that it has issued a press release containing financial results for the three and six months ended 30 Jun 2025. The detailed income statement, balance sheet and cash-flow data are not included within the body of the filing; instead, they are furnished as Exhibit 99.1. No guidance revisions, acquisitions, divestitures, or other material corporate events were disclosed. The document also contains standard forward-looking-statement language and confirms that the company is not an emerging-growth company.
Atlassian (TEAM) Form 4: CEO, co-founder and 10% owner Michael Cannon-Brookes sold a total of 7,765 Class A shares on 22 Jul 2025 under a pre-arranged Rule 10b5-1 plan adopted 20 Feb 2025.
The stock was disposed of in seven separate trades at weighted-average prices between $195.965 and $202.35, generating roughly $1.55 million in gross proceeds. Following the sales, the insider鈥攖hrough CBC Co Pty Ltd as trustee of the Cannon-Brookes Head Trust鈥攃ontinues to hold 375,585 Class A shares, maintaining more than 98% of his prior indirect position and his 10% beneficial-owner status.
No derivative activity or purchases were reported. Given the modest 2% reduction in holdings and the existence of a 10b5-1 plan, the transactions appear routine and are unlikely to materially alter insider alignment, though any CEO liquidation can create short-term sentiment pressure.
Atlassian (TEAM) Form 4: CEO, co-founder and 10% owner Michael Cannon-Brookes sold a total of 7,765 Class A shares on 22 Jul 2025 under a pre-arranged Rule 10b5-1 plan adopted 20 Feb 2025.
The stock was disposed of in seven separate trades at weighted-average prices between $195.965 and $202.35, generating roughly $1.55 million in gross proceeds. Following the sales, the insider鈥攖hrough CBC Co Pty Ltd as trustee of the Cannon-Brookes Head Trust鈥攃ontinues to hold 375,585 Class A shares, maintaining more than 98% of his prior indirect position and his 10% beneficial-owner status.
No derivative activity or purchases were reported. Given the modest 2% reduction in holdings and the existence of a 10b5-1 plan, the transactions appear routine and are unlikely to materially alter insider alignment, though any CEO liquidation can create short-term sentiment pressure.
Atlassian (TEAM) Form 4: CEO, co-founder and 10% owner Michael Cannon-Brookes sold a total of 7,765 Class A shares on 22 Jul 2025 under a pre-arranged Rule 10b5-1 plan adopted 20 Feb 2025.
The stock was disposed of in seven separate trades at weighted-average prices between $195.965 and $202.35, generating roughly $1.55 million in gross proceeds. Following the sales, the insider鈥攖hrough CBC Co Pty Ltd as trustee of the Cannon-Brookes Head Trust鈥攃ontinues to hold 375,585 Class A shares, maintaining more than 98% of his prior indirect position and his 10% beneficial-owner status.
No derivative activity or purchases were reported. Given the modest 2% reduction in holdings and the existence of a 10b5-1 plan, the transactions appear routine and are unlikely to materially alter insider alignment, though any CEO liquidation can create short-term sentiment pressure.
Atlassian (TEAM) Form 4: CEO, co-founder and 10% owner Michael Cannon-Brookes sold a total of 7,765 Class A shares on 22 Jul 2025 under a pre-arranged Rule 10b5-1 plan adopted 20 Feb 2025.
The stock was disposed of in seven separate trades at weighted-average prices between $195.965 and $202.35, generating roughly $1.55 million in gross proceeds. Following the sales, the insider鈥攖hrough CBC Co Pty Ltd as trustee of the Cannon-Brookes Head Trust鈥攃ontinues to hold 375,585 Class A shares, maintaining more than 98% of his prior indirect position and his 10% beneficial-owner status.
No derivative activity or purchases were reported. Given the modest 2% reduction in holdings and the existence of a 10b5-1 plan, the transactions appear routine and are unlikely to materially alter insider alignment, though any CEO liquidation can create short-term sentiment pressure.
FAQ
What is the current stock price of Inspiremd (NSPR)?
What is the market cap of Inspiremd (NSPR)?
What is the core focus of InspireMD Inc.?
How does the MicroNet stent technology work?
In which markets does InspireMD operate?
What clinical evidence supports InspireMD's products?
How does InspireMD differentiate itself from its competitors?
What steps has InspireMD taken towards regulatory approval?
How does InspireMD generate revenue?
What advantages does InspireMD鈥檚 technology offer in stroke prevention?
